NM 3086
Alternative Names: NM-3086Latest Information Update: 14 Jun 2023
At a glance
- Originator NovelMed Therapeutics
- Class Antianaemics; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Alternative complement pathway modulators; Complement C3-C5 convertases inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Dry age-related macular degeneration; Eye disorders; Macular degeneration; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration
Highest Development Phases
- Phase I Anaemia; Paroxysmal nocturnal haemoglobinuria
- Preclinical Dry age-related macular degeneration; Wet age-related macular degeneration
Most Recent Events
- 05 Jun 2023 Efficacy, pharmacodynamics and adverse events data from phase I trial in Paroxysmal nocturnal haemoglobinuria and Anaemia released by NovelMed
- 06 Mar 2023 NM 3086 is available for licensing as of 06 Mar 2023. https://www.novelmed.com/partnersinvestors
- 06 Mar 2023 Preclinical trials in Dry age-related macular degeneration in USA (Intravitreous) before March 2023